|Conatus Pharmaceuticals Inc -- USA Stock|| |
USD 6.43 0.21 3.38%
Senior Vice President - Business Development, Program and Alliance Management
Mr. Daniel L. Ripley serves as Senior Vice President Business Development, Program and Alliance Management of Conatus Pharmaceuticals Inc. He has 15 years of integrated business development experience in the initiation and execution of strategic business transactions in emerging growth life science companies. He has led licensing, commercial analysis, partnering initiatives, and intellectual property enforcement to drive business development of earlytolate stage products in a wide variety of therapeutic areas and technologies. He served as Senior Director of Business Development at Apricus Biosciences from 2011 through 2012, and prior to that was a senior business development consultant to biotechnology companies in the San Diego area from 2010 through 2011, Vice President of Business Development at BioBlocks, Inc. from 2009 through 2010, Senior Director, Head of Business Development at Kalypsys, Inc. from 2006 through 2008, and Director of Business Development at Isis Pharmaceuticals from 2000 through 2006. During this timeframe, he executed multiple licensing and drug discovery collaborations with pharmaceutical and biotechnology companies that included Pfizer, Oncogenex, Alnylam, Amgen, GSK, Sanofi, and Alcon
President Since 2017 MBA
Ripley holds an M.B.A. with an emphasis in Finance and a B.S. in Microbiology, both from San Diego State University.
The company has return on total asset (ROA)
of (13.35) %
which means that it has lost $13.35 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (69.89) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.16 M in liabilities with Debt to Equity (D/E) ratio of 47.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals Inc has Current Ratio of 2.76 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The company was founded in 2005 and is headquartered in San Diego, California. Conatus Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 33 people.Conatus Pharmaceuticals Inc (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 33 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.